Xilio Therapeutics (XLO) Current Deferred Revenue (2024 - 2026)

Xilio Therapeutics has disclosed Current Deferred Revenue across 3 years of filings, most recently posting $31.5 million for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $31.5 million, down 60.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $31.5 million (down 60.07% YoY), and the FY2025 annual result was $40.0 million, up 196.07% from the prior year.
• Current Deferred Revenue came in at $31.5 million for Q1 2026 at Xilio Therapeutics, down from $40.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $79.0 million in Q1 2025 to a low of $13.5 million in Q4 2024.
• The 3-year median for Current Deferred Revenue is $31.5 million (2026), against an average of $36.1 million.
• Across the five-year window, Current Deferred Revenue soared 263.61% in 2025 and plunged 60.07% in 2026, its largest moves.
• Xilio Therapeutics' Current Deferred Revenue stood at $13.5 million in 2024, then soared by 196.07% to $40.0 million in 2025, then retreated by 21.19% to $31.5 million in 2026.
• The last three Current Deferred Revenue figures came in at $31.5 million (Q1 2026), $40.0 million (Q4 2025), and $43.8 million (Q3 2025), per Business Quant data.